Novartis Shares Soar 2.82% on Regulus Acquisition

Novartis (NVS) shares surged 2.82% today, marking the second consecutive day of gains, with a total increase of 3.48% over the past two days. The stock price reached its highest level since March 2025, with an intraday gain of 2.91%.

The strategy of buying NVS shares after they reached a recent high and holding for 1 week resulted in a 71.36% total return over the past 5 years. This indicates that this strategy has been successful, as the total return significantly outperformed the broader market.

Novartis's recent stock price movements have been influenced by several key factors. On May 29, 2025, the company experienced a significant drop of 6.14% in pre-market trading due to investor concerns and market reactions following the approval of a new PNH treatment. This reflects a negative market sentiment towards the company following the treatment approval.

Despite the initial setback, Novartis has taken strategic steps to bolster its position in the market. On May 27, 2025, the company announced the launch of a tender offer to acquire Regulus Therapeutics for $7.00 per share in cash plus a potential $7.00 contingent payment tied to a regulatory milestone. This acquisition is aimed at strengthening Novartis's pipeline in RNA-targeted therapies, potentially influencing its long-term innovation and growth strategy.